Published in Atherosclerosis on December 24, 2008
Nonalcoholic fatty liver disease: an emerging threat to obese and diabetic individuals. Ann N Y Acad Sci (2013) 1.40
KASL clinical practice guidelines: management of nonalcoholic fatty liver disease. Clin Mol Hepatol (2013) 1.08
Antioxidant therapy in nonalcoholic steatohepatitis. Hepat Res Treat (2012) 0.83
Multidisciplinary pharmacotherapeutic options for nonalcoholic Fatty liver disease. Int J Hepatol (2012) 0.83
Concordance of randomized and nonrandomized studies was unrelated to translational patterns of two nutrient-disease associations. J Clin Epidemiol (2011) 0.82
The Mediterranean Lifestyle as a Non-Pharmacological and Natural Antioxidant for Healthy Aging. Antioxidants (Basel) (2015) 0.82
Pharmacotherapy for Nonalcoholic Fatty Liver Disease. Semin Liver Dis (2015) 0.81
Antioxidant vitamin intake and mortality: the Leisure World Cohort Study. Am J Epidemiol (2014) 0.80
Use of vitamin supplements and risk of total cancer and cardiovascular disease among the Japanese general population: a population-based survey. BMC Public Health (2011) 0.78
Lipophilic compound-mediated gene expression and implication for intervention in reactive oxygen species (ROS)-related diseases: mini-review. Nutrients (2010) 0.77
Increased LDL susceptibility to oxidation accelerates future carotid artery atherosclerosis. Lipids Health Dis (2012) 0.77
Comparative efficacy of interventions on nonalcoholic fatty liver disease (NAFLD): A PRISMA-compliant systematic review and network meta-analysis. Medicine (Baltimore) (2016) 0.75
Liraglutide's use in treatment of non-alcoholic fatty liver: an evaluation of the non-alcoholic steatohepatitis study. Hepatobiliary Surg Nutr (2016) 0.75
Reproducibility and validity of a semiquantitative food frequency questionnaire. Am J Epidemiol (1985) 26.13
An investigation of coronary heart disease in families. The Framingham offspring study. Am J Epidemiol (1979) 18.84
Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med (2004) 17.79
Reproducibility and validity of an expanded self-administered semiquantitative food frequency questionnaire among male health professionals. Am J Epidemiol (1992) 17.17
Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta-analysis. JAMA (2007) 11.87
Effects of long-term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial. JAMA (2005) 7.35
Vitamin E consumption and the risk of coronary heart disease in men. N Engl J Med (1993) 6.37
An approach to longitudinal studies in a community: the Framingham Study. Ann N Y Acad Sci (1963) 6.29
Accuracy of death certificates for coding coronary heart disease as the cause of death. Ann Intern Med (1998) 5.63
Vitamin E consumption and the risk of coronary disease in women. N Engl J Med (1993) 5.39
Use of antioxidant vitamins for the prevention of cardiovascular disease: meta-analysis of randomised trials. Lancet (2003) 5.34
Framingham risk score and prediction of lifetime risk for coronary heart disease. Am J Cardiol (2004) 2.89
Randomized trials of vitamin E in the treatment and prevention of cardiovascular disease. Arch Intern Med (2004) 1.19
Vitamin E and vitamin C supplement use and risk of all-cause and coronary heart disease mortality in older persons: the Established Populations for Epidemiologic Studies of the Elderly. Am J Clin Nutr (1996) 1.19
Alpha-tocopherol modulates Cyp3a expression, increases gamma-CEHC production, and limits tissue gamma-tocopherol accumulation in mice fed high gamma-tocopherol diets. Free Radic Biol Med (2005) 1.14
Vitamin E increases the risk of developing heart failure after myocardial infarction: Results from the GISSI-Prevenzione trial. J Cardiovasc Med (Hagerstown) (2006) 1.04
Modulation of Cyp3a11 mRNA expression by alpha-tocopherol but not gamma-tocotrienol in mice. Free Radic Biol Med (2005) 0.90
Vitamin E, nuclear receptors and xenobiotic metabolism. Arch Biochem Biophys (2004) 0.88
High-dosage vitamin E supplementation and all-cause mortality. Ann Intern Med (2005) 0.82
Lower ischemic heart disease incidence and mortality among vitamin supplement users. Can J Cardiol (1996) 0.80
Prediction of coronary heart disease using risk factor categories. Circulation (1998) 48.81
Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation (1998) 19.93
Association of sleep-disordered breathing, sleep apnea, and hypertension in a large community-based study. Sleep Heart Health Study. JAMA (2000) 12.27
Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA (1994) 11.63
Long-term morbidity and mortality of overweight adolescents. A follow-up of the Harvard Growth Study of 1922 to 1935. N Engl J Med (1992) 10.44
Probability of stroke: a risk profile from the Framingham Study. Stroke (1991) 10.14
Atrial fibrillation: a major contributor to stroke in the elderly. The Framingham Study. Arch Intern Med (1987) 8.09
The progression from hypertension to congestive heart failure. JAMA (1996) 7.56
The effects of specific medical conditions on the functional limitations of elders in the Framingham Study. Am J Public Health (1994) 7.38
Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol (1998) 6.76
Epidemiologic assessment of the role of blood pressure in stroke. The Framingham study. JAMA (1970) 6.42
Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am J Epidemiol (1997) 6.10
Stroke risk profile: adjustment for antihypertensive medication. The Framingham Study. Stroke (1994) 5.83
Self-monitoring of blood glucose levels and glycemic control: the Northern California Kaiser Permanente Diabetes registry. Am J Med (2001) 5.68
Epidemiologic assessment of chronic atrial fibrillation and risk of stroke: the Framingham study. Neurology (1978) 5.37
Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. JAMA (1993) 5.21
The preclinical phase of alzheimer disease: A 22-year prospective study of the Framingham Cohort. Arch Neurol (2000) 4.77
Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons. N Engl J Med (1994) 4.74
Association between plasma homocysteine concentrations and extracranial carotid-artery stenosis. N Engl J Med (1995) 4.36
Number of pregnancies and the subsequent risk of cardiovascular disease. N Engl J Med (1993) 4.30
A predictive instrument to improve coronary-care-unit admission practices in acute ischemic heart disease. A prospective multicenter clinical trial. N Engl J Med (1984) 4.29
Inverse association of dietary fat with development of ischemic stroke in men. JAMA (1998) 4.20
Stroke severity in atrial fibrillation. The Framingham Study. Stroke (1996) 4.11
Left atrial size and the risk of stroke and death. The Framingham Heart Study. Circulation (1995) 4.04
Changes in risk factors and the decline in mortality from cardiovascular disease. The Framingham Heart Study. N Engl J Med (1990) 3.99
Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy. Clin Infect Dis (2000) 3.81
The Emerging Risk Factors Collaboration: analysis of individual data on lipid, inflammatory and other markers in over 1.1 million participants in 104 prospective studies of cardiovascular diseases. Eur J Epidemiol (2007) 3.81
Impact of atrial fibrillation on mortality, stroke, and medical costs. Arch Intern Med (1998) 3.79
Variability of body weight and health outcomes in the Framingham population. N Engl J Med (1991) 3.61
Fibrinogen and risk of cardiovascular disease. The Framingham Study. JAMA (1987) 3.59
Morning increase in onset of ischemic stroke. Stroke (1989) 3.52
Psychological predictors of hypertension in the Framingham Study. Is there tension in hypertension? JAMA (1993) 3.42
Depressive symptoms and risk of dementia: the Framingham Heart Study. Neurology (2010) 3.27
Lower cognitive function in the presence of obesity and hypertension: the Framingham heart study. Int J Obes Relat Metab Disord (2003) 3.23
Infarcts of undetermined cause: the NINCDS Stroke Data Bank. Ann Neurol (1989) 3.13
Inflammatory markers and the risk of Alzheimer disease: the Framingham Study. Neurology (2007) 3.12
The Stroke Data Bank: design, methods, and baseline characteristics. Stroke (1988) 3.12
Stroke risk profile, brain volume, and cognitive function: the Framingham Offspring Study. Neurology (2004) 2.97
Are dietary patterns useful for understanding the role of diet in chronic disease? Am J Clin Nutr (2001) 2.94
Systolic blood pressure, arterial rigidity, and risk of stroke. The Framingham study. JAMA (1981) 2.93
Midlife vascular risk factor exposure accelerates structural brain aging and cognitive decline. Neurology (2011) 2.91
The relation of hearing in the elderly to the presence of cardiovascular disease and cardiovascular risk factors. Arch Otolaryngol Head Neck Surg (1993) 2.91
American Heart Association Prevention Conference. IV. Prevention and Rehabilitation of Stroke. Risk factors. Stroke (1997) 2.87
Profile for estimating risk of heart failure. Arch Intern Med (1999) 2.81
Mitral annular calcification and the risk of stroke in an elderly cohort. N Engl J Med (1992) 2.77
Plasma concentration of C-reactive protein and risk of ischemic stroke and transient ischemic attack: the Framingham study. Stroke (2001) 2.71
Maximum likelihood estimation for interval-censored data using a Weibull-based accelerated failure time model. Biometrics (1992) 2.70
Clustering of metabolic factors and coronary heart disease. Arch Intern Med (1999) 2.69
Cigarette smoking as a risk factor for stroke. The Framingham Study. JAMA (1988) 2.68
Untreated blood pressure level is inversely related to cognitive functioning: the Framingham Study. Am J Epidemiol (1993) 2.67
Primary prevention of ischemic stroke: A statement for healthcare professionals from the Stroke Council of the American Heart Association. Stroke (2001) 2.65
Prevalence of dementia and probable senile dementia of the Alzheimer type in the Framingham Study. Neurology (1992) 2.64
Comparison of baseline and repeated measure covariate techniques in the Framingham Heart Study. Stat Med (1988) 2.62
Total serum bilirubin and risk of cardiovascular disease in the Framingham offspring study. Am J Cardiol (2001) 2.57
Computing estimates of incidence, including lifetime risk: Alzheimer's disease in the Framingham Study. The Practical Incidence Estimators (PIE) macro. Stat Med (2000) 2.54
Trends in the prevalence of hypertension, antihypertensive therapy, and left ventricular hypertrophy from 1950 to 1989. N Engl J Med (1999) 2.53
Patient-specific predictions of outcomes in myocardial infarction for real-time emergency use: a thrombolytic predictive instrument. Ann Intern Med (1997) 2.52
Protective effect of fruits and vegetables on development of stroke in men. JAMA (1995) 2.50
Absence of association or genetic linkage between the angiotensin-converting-enzyme gene and left ventricular mass. N Engl J Med (1996) 2.49
Evaluation of subsecond gated helical CT for quantification of coronary artery calcium and comparison with electron beam CT. AJR Am J Roentgenol (2000) 2.49
Secular trends in the prevalence of atrial fibrillation: The Framingham Study. Am Heart J (1996) 2.47
Lifetime risk of dementia and Alzheimer's disease. The impact of mortality on risk estimates in the Framingham Study. Neurology (1997) 2.43
The 'preclinical phase' of probable Alzheimer's disease. A 13-year prospective study of the Framingham cohort. Arch Neurol (1995) 2.42
Predictors of brain morphology for the men of the NHLBI twin study. Stroke (1999) 2.41
Missed diagnoses of acute myocardial infarction in the emergency department: results from a multicenter study. Ann Emerg Med (1993) 2.39
Dietary determinants of iron stores in a free-living elderly population: The Framingham Heart Study. Am J Clin Nutr (1998) 2.38
Sudden coronary death in women. Am Heart J (1998) 2.33
Duration of atrial fibrillation and imminence of stroke: the Framingham study. Stroke (1984) 2.30
Intermittent claudication. A risk profile from The Framingham Heart Study. Circulation (1997) 2.29
Effect of L-dopa on plasma homocysteine in PD patients: relationship to B-vitamin status. Neurology (2003) 2.28
Cerebrovascular and brain morphologic correlates of mild cognitive impairment in the National Heart, Lung, and Blood Institute Twin Study. Arch Neurol (2001) 2.22
Incidence of dementia and probable Alzheimer's disease in a general population: the Framingham Study. Neurology (1993) 2.21
Intracerebral hemorrhage: external validation and extension of a model for prediction of 30-day survival. Ann Neurol (1991) 2.20
Chronic disease in former college students. I. Early precursors of fatal coronary heart disease. Am J Epidemiol (1966) 2.18
Functional limitations and disability among elders in the Framingham Study. Am J Public Health (1992) 2.17